Compare ACDC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | SDGR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 1.3B |
| IPO Year | 2022 | 2020 |
| Metric | ACDC | SDGR |
|---|---|---|
| Price | $3.92 | $17.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.83 | ★ $26.25 |
| AVG Volume (30 Days) | ★ 1.3M | 838.4K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,960,000,000.00 | $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $3.08 | $15.99 |
| 52 Week High | $10.70 | $28.47 |
| Indicator | ACDC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 43.56 |
| Support Level | $3.78 | $17.53 |
| Resistance Level | $4.64 | $19.04 |
| Average True Range (ATR) | 0.30 | 0.74 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 44.79 | 24.77 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.